Abstracts tagged "Myositis"

Abstract Number: 0152 • ACR Convergence 2022
Pm/Scl Patients Have an Expanded Population of CD19+CD21lo/negCD11c+CD11b+ Cells Expressing a Monocyte, Not B Cell, Transcriptome
Erin Wilfong, Leslie Crofford and Rachel Bonami, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: CD19 is considered a canonical B cell lineage marker. Previously, we have reported that CD19+CD21lo/negCD11c+ cells were increased in both systemic sclerosis [PMC8828801] as…
Abstract Number: 0172 • ACR Convergence 2022
Clinical Characteristics and Outcomes of Inflammatory Myositis Related Interstitial Lung Disease: A 15 Year Retrospective Study
Ian Ward¹, Elizabeth Pepper² and Geoffrey Loh², ¹United States Army, Evans, GA, ²DDEAMC, Ft. Gordon, GA
Background/Purpose: Interstitial lung disease (ILD) is a common complication of Idiopathic Inflammatory Myopathy (IIM). This extra-muscular manifestation is a significant source of morbidity and has…
Abstract Number: 1858 • ACR Convergence 2022
A Multi-center Clinical Cohort Study of Chinese Anti-synthetase Syndrome Patients
mingwei tang¹, Qian Wang¹, wei Wei², Pingting Yang³, Xinwang Duan⁴, Hongbin Li⁵, Chanyuan Wu⁶, JIULIANG ZHAO⁷, jia shi¹, Xiaomei Leng⁸, Xinping Tian¹, MENGTAO LI⁹, Yan Zhao¹ and Xiaofeng Zeng¹⁰, ¹Peking Union Medical College Hospital, Beijing, China, ²Tianjin Medical University General Hospital, Tianjin, China, ³The First Hospital of China Medical University, Shenyang, China, ⁴the Second Affiliated Hospital of Nanchang University, Nanchang, China, ⁵Inner Mongolia Medical University, Hohhot City, China, ⁶Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing, China, ⁷Beijing Union Medical College Hospital, Beijing, China, ⁸Peking Union Medical College Hospital, Department of Rheumatology and Clinical Immunology, Beijing, China, ⁹Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, State Key Laboratory of Complex Severe and Rare Diseases, Ministry of Science & Technology, Beijing, China, ¹⁰Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China
Background/Purpose: Based on the Chinese Rheumatology Data Center Inflammatory Myopathy Registry (CRDC-MYO), this study aimed to describe the baseline characteristics of a subgroup of patients…
Abstract Number: 1883 • ACR Convergence 2022
Auto-antibodies Targeting Membrane Repair Proteins Enhances Myositis Phenotype
Shane Bruckner¹, Kassidy Banford², hannah Bulgart², Kevin mcElhanon³, Rohit Aggarwal⁴, Chester Oddis⁵, Noah Weisleder¹ and Wael Jarjour¹, ¹The Ohio State University, Columbus, OH, ²The Ohio State University Wexner Medical Center, Columbus, OH, ³Pfizer Inc., Cambridge, MA, ⁴Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, ⁵University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of disorders in which autoimmune responses produce a chronic state of inflammation resulting in degeneration of skeletal…
Abstract Number: 0153 • ACR Convergence 2022
Obesity Is Associated with Higher Odds of Malignancy Development Among Dermatomyositis Patients
Astia Allenzara¹, Nakisa Sadeghi¹, Carolina Alvarez², Steve Maczuga³, Matthew Helm³, Amanda Nelson² and Galen Foulke¹, ¹University of North Carolina, Chapel Hill, NC, ²University of North Carolina at Chapel Hill, Chapel Hill, NC, ³Penn State Hershey Medical Center, Hershey, PA
Background/Purpose: Dermatomyositis (DM) is an idiopathic inflammatory myopathy with an increased risk of mortality and morbidity from cancer. Across the general population, excess body weight…
Abstract Number: 0176 • ACR Convergence 2022
Diagnostic Accuracy and Clinical Relevance of Muscle Biopsy in Patients with Suspected Myositis
Kastriot Kastrati¹, Nasim NAKHOST LOTFI², Marwa Tawfik³, Ellen Gelpi², Romana Hoeftberger², Hans-Peter Kiener², Daniel Aletaha⁴, Michael Bonelli⁵ and Helga Radner⁵, ¹Division of Rheumatology, Vienna, Austria, ²Medical University Vienna, Vienna, Austria, ³Suez Canal University, Ismailia, Egypt, ⁴Medical University Vienna, Wien, Austria, ⁵Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
Background/Purpose: Diagnosis of idiopathic inflammatory myopathies (IIM) represents a clinical challenge and muscle biopsy is regarded as a fundamental procedure for confirming diagnosis. However, the…
Abstract Number: 1860 • ACR Convergence 2022
Lenabasum, a Cannabinoid Type 2 Receptor Agonist, Activates Diverse Cell-specific Pathways in Whole Blood Leukocytes in Dermatomyositis
Nilesh Kodali¹, Thomas Vazquez², DeAnna Diaz³, Josh Dan⁴, Grant Sprow⁵, Rohan Dhiman⁶, Mariko Ogawa-Momohara⁷, Muhammad Bashir⁶, Meena Sharma⁸ and Victoria Werth⁹, ¹New Jersey Medical School, Coppell, TX, ²FIU Wertheim College of Medicine, Virginia Beach, VA, ³Philadelphia College of Medicine, Philadelphia, PA, ⁴Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, ⁵Albert Einstein College of Medicine, Philadelphia, PA, ⁶University of Pennsylvania, Philadelphia, PA, ⁷Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁸Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁹University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
Background/Purpose: Dermatomyositis (DM) is a systemic autoimmune disease that affects the skin and muscle. Lenabasum, a cannabinoid type 2 receptor (CB2R) agonist, has been developed…
Abstract Number: 1885 • ACR Convergence 2022
Histopathological Patterns of Muscle Involvement and Clinical Correlations in a Retrospective Cohort of Scleroderma Patients
Noemie Le Gouellec¹, Louai Zaidan², Eric Hachulla³, Nicolas Dognon³, Robin Dhote⁴, Sebastien Riviere⁵, Yurdagul Uzunhan⁴, Luc Mouthon⁶ and Jerome Authier⁷, ¹CH Valenciennes, Valenciennes, France, ²CHU Henri Mondor, Creteil, France, ³University of Lille, LILLE, France, ⁴Hopital Avicenne - Paris University, Bobigny, France, ⁵Hopital Saint Antoine - Paris University, Paris, France, ⁶Hopital Cochin - Paris University, Paris, France, ⁷Paris Est - Creteil University, Creteil, France
Background/Purpose: Muscle involvement in systemic sclerosis (SSc) has been shown to be heterogeneous. Histopathological pattern seems to be associated with prognosis, but studies evaluating the…
Abstract Number: 0154 • ACR Convergence 2022
Anti-SMN Autoantibodies in Mixed Connective Tissue Disease Are Associated with a Scleromyositis Phenotype
Hajar El Kamouni¹, Alexandra Albert², Sabrina Hoa³, Darya S. Jalaledin⁴, Josiane Bourre-Tessier⁵, Eric Rich⁵, Jean-Richard Goulet⁶, Martial Koenig⁷, Minoru Satoh⁸, Marvin Fritzler⁹, May Choi¹⁰, Yves Troyanov¹¹, Jean-Luc Senécal⁵ and Océane Landon-Cardinal⁵, ¹Division of Rheumatology, Centre Hospitalier de l'Université de Montréal, Laval, Canada, ²Division of Rheumatology, Centre Hospitalier de l'Université Laval, Québec, QC, Canada, ³University of Montreal, Montréal, QC, Canada, ⁴Division of Internal Medicine, Centre Hospitalier de l'Université de Sherbrooke, Saint-Lambert, Canada, ⁵Division of Rheumatology, Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada, ⁶Division of Rheumatology, Centre Hospitalier de l'Université de Montréal, Saint-Lambert, Canada, ⁷Division of Internal Medicine, Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada, ⁸Department of Human, Information and Science, University of Occupational Environmental Health, Kitakyusyu Fukuoka, Japan, ⁹University of Calgary, Calgary, AB, Canada, ¹⁰Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ¹¹Division of Rheumatology, Hôpital du Sacré-Coeur de Montréal, Montréal, QC, Canada
Background/Purpose: The survival of motor neuron (SMN) is a ubiquitous macromolecular complex, located in the Cajal body of mammalian nuclei, with an essential role in…
Abstract Number: 0177 • ACR Convergence 2022
COVID-19 Vaccination-related Short-term Adverse Events in Patients with Idiopathic Inflammatory Myositis and Autoimmune Multimorbidity: Results from the COVID-19 Vaccination in Autoimmune Diseases Survey
Mrinalini Dey¹, Naveen R², Elena Nikiphorou³, Parikshit Sen⁴, James B. Lilleker⁵, Vishwesh Agarwal⁶, Sinan Kardes⁷, Jessica Day⁸, Marcin Milchert⁹, Mrudula Joshi¹⁰, Tamer A Gheita¹¹, Babur Salim¹², Tsvetelina Velikova¹³, Abraham Edgar Gracia-Ramos¹⁴, Ioannis Parodis¹⁵, Albert Selva O’Callaghan¹⁶, Minchul Kim¹⁷, Tulika Chatterjee¹⁷, Ai Lyn Tan¹⁸, Ashima Makol¹⁹, Arvind Nune²⁰, Lorenzo Cavagna²¹, Miguel Angel Saavedra Salinas²², Samuel Shinjo²³, Nelly Ziade²⁴, Johannes Knitza²⁵, Masataka Kuwana²⁶, Oliver Distler²⁷, Hector Chinoy²⁸, John Pauling²⁹, Chris Wincup³⁰, Vikas Agarwal², Rohit Aggarwal³¹ and Latika Gupta³², ¹Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, United Kingdom, ²Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ³Leiden University Medical Center & King's College London, London, United Kingdom, ⁴Maulana Azad Medical College, New Delhi, India, ⁵The University of Manchester, Manchester, United Kingdom, ⁶Mahatma Gandhi Missions Medical College, Lucknow, India, ⁷Istanbul University, Istanbul, Turkey, ⁸Walter and Eliza Hall Institute, Melbourne, Australia, ⁹Pomeranian Medical University in Szczecin, Szczecin, Poland, ¹⁰Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospitals, Pune, India, ¹¹Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt, ¹²Fauji foundation hospital Rawalpindi, Rawalpindi, Pakistan, ¹³Sofia University St. Kliment Ohridski, Sofia, Bulgaria, ¹⁴Instituto Mexicano del Seguro Social, Ciudad de México, Mexico, ¹⁵Karolinska Institutet, Stockholm, Sweden, ¹⁶Hospital Universitari Vall d'Hebron, Barcelona, Spain, ¹⁷University of Illinois College of Medicine Peoria, Peoria, IL, ¹⁸University of Leeds, Leeds, United Kingdom, ¹⁹Mayo Clinic, Rochester, MN, Rochester, MN, ²⁰Southport and Ormskirk Hospital NHS Trust, Southport, United Kingdom, ²¹Università di Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, Pavia, Italy, ²²IMSS, Ciudad de México, Mexico, ²³Faculdade de Medicina FMUSP, Universidade de São Paulo, São Paulo, Brazil, ²⁴Saint-Joseph University, Beirut, Lebanon, ²⁵Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-UniversityErlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ²⁶Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ²⁷Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ²⁸The University of Manchester, Sale, United Kingdom, ²⁹North Bristol NHS Trust, Bristol, United Kingdom, ³⁰Rayne Institute, University College London, London, United Kingdom, ³¹Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, ³²Royal Wolverhampton Trust, Wolverhampton/University of Manchester, United Kingdom
Background/Purpose: COVID-19 vaccines are safe and effective, though patients with rare rheumatic diseases like idiopathic inflammatory myositis (IIMs), and those with multiple comorbidities continue to…
Abstract Number: 1862 • ACR Convergence 2022
Lenabasum Reduces IFNγ and pIRF3 in Dermatomyositis Skin: Biomarker Results from a Double-Blind Phase 3 International Randomized Controlled Trial
Thomas Vazquez¹, Meena Sharma¹, Rui Feng², DeAnna Diaz³, Nilesh Kodali¹, Josh Dan³, Madison Grinnell³, Emily Keyes³, Grant Sprow³, Barbara White⁴ and Victoria Werth³, ¹Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, ³Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, ⁴Corbus Pharmaceuticals, Pleasanton, CA
Background/Purpose: Dermatomyositis (DM) is an autoimmune connective tissue disease that primarily affects the skin and lung; few effective treatment options are available. Lenabasum is a…
Abstract Number: 1886 • ACR Convergence 2022
Statin-induced Immune-mediated Miopathy: Treatment with Glucocorticoid-free Protocols and Role of Muscle Biopsy in the Follow-up
David Martínez-López¹, Piotr Szczęsny², Inger Nennesmo³, Karina Gheorghe⁴, Antonella Notarnicola⁵, Helene Alexanderson⁶, Ingrid Lundberg⁷ and Maryam Dastmalchi⁸, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Department of Rheumatology, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland. Department of Neurology, Medical University of Warsaw, Warsaw, Poland, ³Department of Pathology, Karolinska University Hospital,Pathology, Karolinska University Hospital., Stockholm, Sweden, ⁴Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet. Rheumatology, Karolinska University Hospital Stockholm, Sweden. Center for Molecular Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁵Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁶Karolinska Institutet, Stockholm, Sweden, ⁷Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden, ⁸Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Statin-induced immune mediated necrotizing myopathy (IMNM) is a recently identified autoimmune condition associated with anti-3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) antibodies, characterized by progressive muscle weakness leading…
Abstract Number: 0155 • ACR Convergence 2022
Validity of the Mawdsley Calcinosis Questionnaire in Adult and Juvenile Dermatomyositis (DM, JDM) Patients with Calcinosis
Sarvar Nazir¹, Kelly Rouster-Stevens², Julie Fuller³, Hanna Kim⁴, Vy Do⁵, Rita Volochayev⁶, Anna Jansen⁶, Nastaran Bayat⁷, Lisa G Rider⁸ and Adam Schiffenbauer⁶, ¹National Institutes of Health, Charlotte, NC, ²Emory University/Children's Healthcare of Atlanta, Atlanta, GA, ³UT Southwestern, Frisco, TX, ⁴Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences; Juvenile Myositis Therapeutic and Translation Studies Unit, PTRB, NIAMS, NIH, Bethesda, MD, ⁵UT Austin Dell Medical School, Austin, TX, ⁶National Institutes of Health, Bethesda, MD, ⁷Social & Scientific Systems, Inc., a DLH Holdings Corp (DLH) company, Bethesda, MD, ⁸Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health, Bethesda, MD
Background/Purpose: Calcinosis is a complication of the idiopathic inflammatory myopathies (IIM) in which calcium salts are deposited in and around soft tissue, which can impact…
Abstract Number: 0178 • ACR Convergence 2022
Muscle Fibres Play a Critical Role in Therapeutic Response of Myositis to Glucocorticoids Through Polarisation of the Inflammatory Infiltrate by a Paracrine Mechanism
Margherita Giannini¹, Daniela Rovito², Léa Debrut³, Céline Keime⁴, Beatrice Lannes⁵, Anne-Laure Charles³, Delphine Duteil², Bernard Geny⁶, Daniel Metzger², Gilles Laverny² and Alain Meyer¹, ¹Service de Physiologie et explorations fonctionnelles, CHU, Strasbourg ; Centre de Référence des Maladies Autoimmunes Rares, CHU, Strasbourg ; UR3072, Centre de Recherche en Biomédecine, University of Strasbourg, Strasbourg, France, ²University of Strasbourg, CNRS UMR7104, INSERM U1258, IGBMC, F-67400, Illkirch, France, ³UR3072 Centre de Recherche en Biomédecine, University of Strasbourg, Strasbourg, France, ⁴University of Strasbourg, CNRS UMR 7104, INSERM UMR-S 1258, IGBMC, F-67400, Illkirch, France, ⁵Département de pathologie, Centre de référence des maladies neuromusculaires, CHU Strasbourg, University of Strasbourg, Strasbourg, France, ⁶Service de Physiologie et explorations fonctionnelles, CHU, Strasbourg ; UR3072 Centre de Recherche en Biomédecine, University of Strasbourg, Strasbourg, France
Background/Purpose: Glucocorticoids (GC) are the first line treatment for myositis patients. They improve muscle strength, yet muscle recovery is generally partial and long lasting treatment…
Abstract Number: 1864 • ACR Convergence 2022
Hepatitis B Exposure and Infection in Idiopathic Inflammatory Myopathies: Prevalence, Presentation, and Treatment Response
Ana Valle¹, Xianhong Xie² and Shereen Mahmood³, ¹Montefiore Medical Center, New York, NY, ²Department of Epidemiology & Population Health/Albert Einstein College of Medicine, Bronx, NY, ³Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY
Background/Purpose: Hepatitis B (HBV) screening in patients with autoimmune conditions is vital prior to the initiation of immunosuppressive therapy given the risk of HBV reactivation.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].